07:00 , May 13, 2013 |  BC Week In Review  |  Clinical News

Royal DSM preclinical data

In mice, single doses of 1.7, 5 and 15 µg recombinant hemagglutinin (rHA) vaccine with or without adjuvant given 21 days before a lethal H1N1 viral challenge led to survival rates of 80-100%. Additionally, complete...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Clinical News

H5N1 influenza vaccine: Phase I started

Not-for-profit Fraunhofer USA Center for Molecular Biotechnology (Newark, Del.) began a double-blind, placebo-controlled, dose-escalation Phase I trial to evaluate HAI-05 in 260 volunteers. Fraunhofer developed the vaccine using iBioLaunch technology from iBio, which owns the...
07:00 , Jul 16, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma Ewing's sarcoma breakpoint region 1 (EWSR1; EWS-Fli1); DEAH (Asp-Glu-Ala-His) box polypeptide 9 (DHX9; RHA) In vitro and mouse studies identified small molecule inhibitors of...
07:00 , Aug 30, 2004 |  BioCentury  |  Tools & Techniques

Sugar-coated delivery

Targeting toxic drugs only to where they are needed in the body is a goal of many drug delivery technologies. Glycoform Ltd. believes that its sugar-based LEAPT delivery system will do just that by taking...
07:00 , May 3, 2004 |  BioCentury  |  Product Development

Protein Sciences: No Yolk

Protein Sciences Corp. believes its FluBlOk influenza vaccine, which is manufactured using the company's baculovirus protein expression system in an insect cell line, will be safer and less resource-intensive than the egg-based manufacturing process for...
07:00 , May 14, 2001 |  BC Week In Review  |  Company News

Symyx, Rhodia deal

SMMX will use its combinatorial technologies to discover improved materials for RHA’s specialty chemical business. RHA will fund SMMX’s research, and will have exclusive commercialization rights to materials from the collaboration. SMMX also will receive...
07:00 , May 9, 2001 |  BC Extra  |  Company News

Symyx chemicals deal with Rhodia

SMMX will use its combinatorial technologies to discover improved materials for RHA's specialty chemical business. RHA will fund SMMX's research, and will have exclusive commercialization rights to materials from the collaboration. SMMX also will receive...
07:00 , Jul 31, 2000 |  BC Week In Review  |  Company News

ChiRex, Rhodia deal

RHA, a specialty chemicals company, agreed to acquire CHRX for $31.25 per share in cash, valuing CHRX at $510 million. CHRX provides product development and manufacturing services to the pharmaceutical industry. ChiRex Inc. (CHRX), Stamford,...
07:00 , Jul 24, 2000 |  BC Extra  |  Top Story

Rhodia acquires ChiRex

RHA agreed to acquire CHRX for $31.25 per share in cash, valuing CHRX at $510 million. Rhodia is a specialty chemicals company, and CHRX is a provider of product development services and manufacturing to the...